1 / 20

AIDS 2010: Track B (Clinical Science) Highlights

AIDS 2010: Track B (Clinical Science) Highlights. Dr. Andrew Kambugu, Uganda (Lead) Jain Vivek, USA Dr. Gabriel Chamie, USA Dr. Sabrina Kitaka-Bakera, Uganda Dr. Jose Arribas, Spain Dr. N. Kumarasamy, India Dr. Annie Luetkemeyer, USA Dr. Ted Ruel UCSF, USA. Track B Stats.

gage-pierce
Télécharger la présentation

AIDS 2010: Track B (Clinical Science) Highlights

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. AIDS 2010: Track B (Clinical Science) Highlights Dr. Andrew Kambugu, Uganda (Lead) Jain Vivek, USA Dr. Gabriel Chamie, USA Dr. Sabrina Kitaka-Bakera, Uganda Dr. Jose Arribas, Spain Dr. N. Kumarasamy, India Dr. Annie Luetkemeyer, USA Dr. Ted Ruel UCSF, USA

  2. Track B Stats

  3. Structure of Report • ART: New Drugs and Novel Treatment Strategies • New ART products • Simplification / Switching • When to Start ART • Co-infections/Co-morbidities • HIV/TB co-infection • HIV/Hepatitis co-infection • HIV and Malignancies • Complications of HIV and ART • Monitoring of ART • Paediatrics

  4. Promising Next-generation INI-ING112276

  5. A Nucleoside-Sparing Strategy- The PROGRESS Study

  6. Treatment Simplification- The SPIRAL Study MOAB0103-SPIRAL SLIDE

  7. Treatment Simplification- The SPARTAN Study

  8. When to Start ART- The CASCADE Collaboration CASCADE-1 AIDS 2010: THLBB201

  9. When to Start ART- The CASCADE Collaboration CASCADE-2 AIDS 2010: THLBB201

  10. When to Start ART- The CHER Trial Analysis (Paeds)

  11. When to Start ART- The CAMELIA Trial (TB)

  12. TB/HIV Co-Infection- The Role of IPT in RLS (MOAB0305) AIDS 2010: MOAB0305

  13. HIV/Hepatitis Co-Infection- Risk of Fractures (TUAB0104) TUAB0104 Slide AIDS 2010: TUAB0104

  14. HIV and Malignancies- Higher Burden in HIV (WEAB0101) AIDS 2010: WEAB0101

  15. HIV and Bone Disease- Association with ART Regimens (WEAB0304) ?WEAB0304- HIV Comps AIDS 2010: WEAB0304

  16. ART Monitoring: VL vs Non VL sites (THAB0102) THAB0102: Monitoring Slide AIDS 2010: THAB0102

  17. Paediatric ART: The PENPACT Study (THLBB104) THLBB104-PENPACT Slide AIDS 2010: THLBB104

  18. What Next After CAPRISA 004?

  19. Key Messages • Newer Drugs may offer simpler, less toxic regimens while maintaining HIV suppression • Nucleoside-sparing regimens (SPARTAN, PROGRESS) • Start ART earlier • Certain: CD4 less than 350, TB, Peads • Less certain: CD4 less than 500 but >350 • TB and ART: Initiate ART at the earliest opportunity • The CAMELIA

  20. Track B Rapporteur Team • Dr. Andrew D Kambugu IDI Uganda • Dr. Jain Vivek, UCSF, USA • Dr. Gabriel Chamie, UCSF, USA • Dr. Sabrina Kitaka-Bakera, Makerere, Uganda • Dr. Jose Arribas, Madrid, Spain • Dr. N. Kumarasamy, Chenai, India • Dr. Annie Luetkemeyer, UCSF, USA • Dr. Ted Ruel UCSF, USA

More Related